Welcome to our dedicated page for Polaryx Therapeutics news (Ticker: PLYX), a resource for investors and traders seeking the latest updates and insights on Polaryx Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Polaryx Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Polaryx Therapeutics's position in the market.
Polaryx (Nasdaq: PLYX) presented preclinical PLX-200 (reformulated gemfibrozil) data for Krabbe disease at WORLDSymposium on February 6, 2026. Findings in GALC-/- mice showed reduced astrogliosis and psychosine, myelin protection, restored motor function and increased lifespan. Polaryx received an FDA safe-to-proceed letter in October 2025 and plans to start the Phase 2 SOTERIA basket trial in H1 2026 to evaluate PLX-200 across multiple lysosomal storage disorders.
Polaryx Therapeutics (Nasdaq: PLYX) announced three new board appointments effective January 29, 2026: Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D., while Andrew O ceased board service on the same date.
The company highlighted these additions as strengthening governance and expertise as its lead candidate, PLX-200, advances into an IND-approved SOTERIA Phase 2 basket trial and as Polaryx continues as a newly listed Nasdaq public company.
Polaryx (NASDAQ: PLYX) will present late-breaking preclinical data on PLX-200 for Krabbe disease at the 22nd Annual WORLDSymposium™ (Feb 2-6, 2026).
Data support advancing the Phase 2 SOTERIA basket trial (CLN2, CLN3, Krabbe, Sandhoff). The company received an FDA safe to proceed letter in October 2025 and plans trial initiation in the first half of 2026. Presentation: Feb 6, 2026, 9:00am PST; presenter Shrijay Vijayan, Ph.D., MBA.
Polaryx Therapeutics (NASDAQ: PLYX) announced a direct listing on the Nasdaq Capital Market effective February 2, 2026, with shares trading under the ticker PLYX. The company is a clinical-stage biotech focused on novel therapies for rare pediatric lysosomal storage disorders.
Polaryx highlighted a planned launch in H1 2026 of SOTERIA, a single-arm, open-label Phase 2 basket trial evaluating lead candidate PLX-200 for multiple LSD indications. Maxim Group served as exclusive financial advisor; Gibson Dunn and Brownstein Hyatt Farber Schreck served as legal and Nevada counsel, respectively.
Polaryx Therapeutics (Nasdaq:PLYX) announced that its common stock has been approved for listing on the Nasdaq Capital Market under the ticker PLYX, with trading expected to begin on or about February 2, 2026. The company plans a direct listing and will launch a new Investor Relations website.
Polaryx said it is preparing to initiate SOTERIA, a single-arm, open-label Phase 2 basket trial of lead candidate PLX-200 assessing safety, tolerability, and clinical activity across multiple lysosomal storage disorder indications.
FAQ
What is the current stock price of Polaryx Therapeutics (PLYX)?
What is the market cap of Polaryx Therapeutics (PLYX)?
